ANIX (Anixa Biosciences) Moat Score: 3/10 (As of Jun. 28, 2026)


ANIX Anixa Biosciences Inc ANIX
27 GF Score
Price $2.79
! 3 Warning Signs
View Full Analysis

What is Anixa Biosciences Moat Score?

Anixa Biosciences ANIX +5.88% 27 Moat Score is 3 as of Jun. 28, 2026. GuruFocus rates ANIX with a GF Score™ of 27/100. The stock has 3 warning signs investors should review. Among 1,402 Biotechnology companies, Anixa Biosciences ranks better than 75.46% on this metric.

Anixa Biosciences has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Anixa Biosciences has No Moat: Anixa Biosciences has very weak competitive advantages. It lacks market leadership, significant customer switching costs, and strong brand strength, resulting in a transient advantage at best.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Anixa Biosciences might have No Moat - Very weak/transient advantages.

Anixa Biosciences  (NAS:ANIX) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Anixa Biosciences Moat Score Related Terms

ANIX vs PYPD, LONA, SGMO: Moat Score Comparison

For the Biotechnology subindustry, Anixa Biosciences's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anixa Biosciences Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anixa Biosciences's Moat Score distribution charts can be found below:

* The bar in red indicates where Anixa Biosciences's Moat Score falls into.


ANIX
27GF Score
Anixa Biosciences Inc ANIX
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Anixa Biosciences (ANIX) has a Moat Score of 3 as of Jun. 28, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Anixa Biosciences ranks #344 out of 1402 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Anixa Biosciences' Moat Score too high?
Anixa Biosciences' current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Anixa Biosciences' value of 3 is 50% above this industry median. Based on the distribution chart, Anixa Biosciences ranks #344 out of 1402 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Anixa Biosciences has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Anixa Biosciences' Moat Score compare to PYPD and LONA?
According to the Biotechnology industry distribution chart, Anixa Biosciences ranks #344 out of 1402 companies for Moat Score. This places Anixa Biosciences in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Anixa Biosciences' value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,402 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anixa Biosciences's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anixa Biosciences's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anixa Biosciences stock overvalued right now?
Anixa Biosciences (ANIX) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Anixa Biosciences' overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Anixa Biosciences (ANIX), the current Moat Score is 3 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anixa Biosciences Business Description

Other Exchanges CY71:Germany
Address 3150 Almaden Expressway, Suite 250, San Jose, CA, USA, 95118
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
27GF Score

Get the complete analysis for ANIX

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.79
Price